Day: March 18, 2026

Purpose Investments Inc. Announces March 2026 Distributions

Written by Customer Service on March 18, 2026. Posted in Dividend Reports And Estimates.

TORONTO, March 18, 2026 (GLOBE NEWSWIRE) — Purpose Investments Inc. (“Purpose”) is pleased to announce distributions for the month of March 2026 for its open-end exchange-traded funds and closed-end funds (“the Funds”). The ex-distribution date for all Open-End Funds is March 27, 2026. The ex-distribution date for all closed-end funds is March 31, 2026. Open-End Funds Ticker Symbol Distribution per share/unit Record Date Payable Date Distribution FrequencyApple (AAPL) Yield Shares Purpose ETF – ETF Units APLY $0.1667 03/27/2026 04/02/2026 MonthlyPurpose Couche-Tard (ATD) Yield Shares ETF – ETF Series ATDY $0.0650 03/27/2026 04/02/2026 MonthlyPurpose Canadian Financial Income Fund – ETF Series BNC $0.1225¹ 03/27/2026 04/02/2026 MonthlyPurpose Global Bond Fund – ETF Units BND $0.0866 03/27/2026 04/02/2026 MonthlyPurpose...

Positive VAX-31 Phase 1/2 Adult Data Published in The Lancet Infectious Diseases Highlight Best-in-Class Potential of Vaxcyte’s 31-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate

Written by Customer Service on March 18, 2026. Posted in Public Companies.

Based on the Strength of Unprecedented Results from the Positive Phase 1/2 Study in Adults Aged 50 and Older, Vaxcyte Advanced VAX-31 High Dose into Comprehensive Phase 3 Adult Program; Topline Data from the OPUS-1 Pivotal Noninferiority Trial Expected in the Fourth Quarter of 2026 At All Doses Studied, VAX-31 Demonstrated Robust Opsonophagocytic Activity and Immunoglobulin G Immune Responses for All 31 Serotypes and Was Observed to be Well Tolerated with a Safety Profile Similar to Prevnar 20® Results Further Validate Potential of Vaxcyte’s Carrier-Sparing Platform to Deliver Broadest-Spectrum PCV Candidates that Provide Protection Against Both Currently Circulating and Historically Prevalent Serotypes VAX-31 is Designed to Cover ~95% of Invasive Pneumococcal Disease (IPD) and ~88% of Pneumococcal Pneumonia in U.S. Adults Aged 50 and...

Preferred Bank Announces Quarterly Dividend

Written by Customer Service on March 18, 2026. Posted in Dividend Reports And Estimates.

LOS ANGELES, March 18, 2026 (GLOBE NEWSWIRE) — Preferred Bank (NASDAQ: PFBC), one of the larger independent commercial banks in California, today reported that the Board of Directors has declared a quarterly cash dividend of $0.80 per share, payable on April 21, 2026 to holders of record on April 7, 2026. About Preferred Bank Preferred Bank is one of the larger independent commercial banks headquartered in California. The Bank is chartered by the State of California, and its deposits are insured by the Federal Deposit Insurance Corporation, or FDIC, to the maximum extent permitted by law. The Bank conducts its banking business from its main office in Los Angeles, California, and through twelve full-service branch banking offices in California (Alhambra, Century City, City of Industry, Torrance, Arcadia, Irvine (2), Diamond Bar,...

VitalHub Reports Fourth Quarter 2025 Results

Written by Customer Service on March 18, 2026. Posted in Earnings Releases And Operating Results.

Annual Recurring Revenue (“ARR”)⁽¹⁾ up 35% YoY to $96.1 millionTotal Revenue up 52% YoY to $31.4 millionAdjusted EBITDA⁽¹⁾ up 47% YoY to $7.4 million TORONTO, March 18, 2026 (GLOBE NEWSWIRE) — Vitalhub Corp. (TSX:VHI) (OTCQX:VHIBF) (the “Company” or “VitalHub”) announced today it has filed its Consolidated Financial Statements and Management’s Discussion and Analysis report for the year ended December 31, 2025 with the Canadian securities authorities. These documents may be viewed under the Company’s profile at www.sedarplus.com. “2025 was a milestone year for VitalHub, surpassing $100 million in revenue. In the fourth quarter, we achieved 10% annual organic ARR⁽¹⁾ growth and 24% adjusted EBITDA as a percentage of revenue⁽¹⁾,” said Dan Matlow, CEO of VitalHub. “We made significant acquisitions and filled in gaps in our portfolio...

Itron and Ausgrid Advance Energy Resource Integration to Millions of Consumers in Eastern Australia

Written by Customer Service on March 18, 2026. Posted in Public Companies.

Ausgrid Deploys Itron Solution to Ensure Grid Reliability and Compliance with Market Requirements LIBERTY LAKE, Wash., March 18, 2026 (GLOBE NEWSWIRE) — Itron, Inc. (NASDAQ: ITRI), which is innovating new ways for utilities and cities to manage energy and water, announced that it is extending its collaboration with Ausgrid, the largest distributor of electricity on Australia’s east coast, to deploy Itron’s IntelliFLEX Low Voltage Distributed Energy Resource Management System (LV DERMS), which is specifically designed to enable electricity distributors like Ausgrid to manage Consumer Energy Resources (CERs), including rooftop solar, battery systems and electric vehicles. Australians are installing rooftop solar in record numbers. In New South Wales (NSW), on Australia’s east coast, around 1 million households and small businesses...

Itafos Q4 2025 and Full Year 2025 Operational and Financial Results – A Year of Superior Execution

Written by Customer Service on March 18, 2026. Posted in Earnings Releases And Operating Results.

HOUSTON, March 18, 2026 (GLOBE NEWSWIRE) — Itafos Inc. (TSX-V: IFOS) (OTCQX: ITFS) (the “Company” or “Itafos”) today reported its Q4 2025 and full year 2025 financial results and provided a corporate update. The Company’s financial statements and management’s discussion and analysis for the three months and year ended December 31, 2025 are available under the Company’s profile at www.sedarplus.ca and on the Company’s website at www.itafos.com. All figures are in thousands of US Dollars except as otherwise noted. A recorded webcast of management’s commentary reviewing the Q4 2025 financial results and an update on the business will be available on the Company’s website on Monday, March 23, 2026 (see details below). CEO Commentary Chief Executive Officer David Delaney commented, “we are pleased to report another quarter and year of...

CVB Financial Corp. Announces 146th Consecutive Quarterly Cash Dividend

Written by Customer Service on March 18, 2026. Posted in Dividend Reports And Estimates.

Ontario, CA, March 18, 2026 (GLOBE NEWSWIRE) — CVB Financial Corp. (NASDAQ: CVBF) (the “Company”) announced a twenty cent ($0.20) per share cash dividend with respect to the first quarter of 2026. This dividend was approved at the Company’s regularly scheduled Board of Directors meeting held on March 18, 2026. The quarterly dividend will be payable on or about April 15, 2026, to shareholders of record as of April 01, 2026. “Our consistent and strong financial performance has enabled the Bank to announce our 146th consecutive quarterly cash dividend to be paid to our shareholders,” said David A. Brager, President and Chief Executive Officer. Corporate OverviewCVB Financial Corp. (“CVBF”) is the holding company for Citizens Business Bank, National Association. CVBF is one of the 10 largest bank holding companies headquartered in California...

Alvotech Q4 2025 and Full Year 2025 Financial Results

Written by Customer Service on March 18, 2026. Posted in Earnings Releases And Operating Results.

REYKJAVIK, Iceland, March 18, 2026 (GLOBE NEWSWIRE) — Alvotech (NASDAQ US: ALVO, ICELAND: ALVO, STOCKHOLM: ALVO SDB) Financial Highlights A supplemental long‑form earnings release providing additional operational details and business update for Q4 2025 and the full year is available at: https://investors.alvotech.com/earnings-calendar The supplemental document is provided solely for reference and is not part of this SEC Form 6‑K. The Form 6‑K should not be read together with, or construed as referring to, the supplemental long‑form release. Q4 2025 HighlightsTotal revenues1 were $173 million, up 13% Year-on-Year (YoY) Adjusted EBITDA1 was $69 million with Gross Margin at 66% AVT05 was approved as a biosimilar to Simponi® in the UK and European Economic Area (EEA) AVT03 was approved as a biosimilar to Prolia® and Xgeva® in the...

Alvotech Q4 2025 and Full Year 2025 Financial Results

Written by Customer Service on March 18, 2026. Posted in Earnings Releases And Operating Results.

A supplemental long‑form earnings release providing additional operational details and business update for Q4 2025 and the full year is available at: https://investors.alvotech.com/earnings-calendar The supplemental document is provided solely for reference and is not part of this SEC Form 6‑K. The Form 6‑K should not be read together with, or construed as referring to, the supplemental long‑form release. Financial Highlights Q4 2025 HighlightsTotal revenues1 were $173 million, up 13% Year-on-Year (YoY) Adjusted EBITDA1 was $69 million with Gross Margin at 66% AVT05 was approved as a biosimilar to Simponi® in the UK and European Economic Area (EEA) AVT03 was approved as a biosimilar to Prolia® and Xgeva® in the EEA The EMA accepted for review a marketing application for AVT23, referencing Xolair® After the end of the quarter, Alvotech...

Future Mineral Closes Second Tranche of Private Placement

Written by Customer Service on March 18, 2026. Posted in Public Companies.

TORONTO, March 18, 2026 (GLOBE NEWSWIRE) — Future Mineral Resources Inc. (“Future Mineral” or the “Company”) (TSX: FMR) is pleased to announce that it has closed a second tranche (the “Second Tranche”) of a previously announced non-brokered private placement financing of up to 15 million common shares at a price of $0.30 per share for gross proceeds of up to $4.5m (the “Offering”). For more information about the Offering and first tranche closing (the “First Tranche”), please see the Company’s press releases dated January 7, 2026, February 2, 2026, and March 13, 2026, each of which is available under the Company’s SEDAR+ profile at www.sedarplus.ca. Pursuant to the Second Tranche, Future Mineral issued 316,667 common shares at a price of $0.30 per share for gross proceeds of approximately $95,000. The securities issued in connection...

Day: March 18, 2026

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals